- Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2018 Academic Article GET IT
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biology of Blood and Marrow Transplantation.
Times cited: 2
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care.
Blood Cancer Journal.
Times cited: 6
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents.
Journal of Clinical Oncology.
Times cited: 28
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Journal of Clinical Investigation.
Times cited: 99
Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Critical Reviews in Oncology and Hematology.
Times cited: 18